FDA Approves New Test To Help Determine If Breast Cancer Patients Are Candidates For

[News]

The U.S. Food and Drug Administration approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment. The test, called Inform Dual ISH, allows for measurement of the number of copies of the HER2 gene in tumor tissue...

More... (http://www.medicalnewstoday.com/releases/228666.php)